Timing of neurorehabilitation and subsequent Alzheimer's disease risk in patients with moderate to severe traumatic brain injury: A nationwide retrospective cohort study in the United States
Journal of Alzheimer’s Disease · 2025
DOI: 10.1177/13872877251385262 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Alzheimer’s Disease, 2025. Verfasst von Austin A Kennemer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Brain Injuries, Traumatic, Neurological Rehabilitation, Time-to-Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIAAA NIH HHS, NCATS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
Traumatic brain injury (TBI) is associated with an increased risk of Alzheimer's disease (AD). It is unknown if prompt neuro-rehabilitative treatment following moderate or severe TBI mitigates this risk compared with delayed treatment.
Objective
To determine whether immediate neuro-rehabilitative treatment following moderate or severe TBI reduces the risk of AD and related cognitive outcomes compared with delayed treatment.
Methods
We conducted a retrospective cohort using the TriNetX Analytics Platform, which includes health records from over 100 million US patients. Adults aged 50–90 years with moderate or severe TBI were included if they received immediate treatment (within 1 week) or delayed treatment (>1 week). Outcomes were AD risk at 3- and 5-year follow-up, with additional outcomes of mild cognitive impairment (MCI), dementia, and AD-related medication prescriptions. Cox proportional hazards models were applied to propensity score–matched cohorts, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated.
Results
Of 37,081 eligible patients, 17,636 remained after propensity score matching. Immediate treatment was associated with lower AD risk compared with delayed treatment (HR, 0.59; 95% CI, 0.41–0.86 at 3 years; HR, 0.70; 95% CI, 0.52–0.94 at 5 years). Similar risk reductions were observed for MCI, dementia, and AD-related medication use.
Conclusions
Immediate treatment following moderate or severe TBI was associated with significantly reduced risk of AD and related cognitive decline. These findings suggest that prompt intervention may mitigate long-term neurodegenerative consequences of TBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA.
Förderung
- NIA NIH HHS
- NIAAA NIH HHS
- NCATS NIH HHS
- National Institute on Aging
- National Center for Advancing Translational Sciences
Zitieren
APA
Kennemer, A. A., Gao, Z., Davis, P. B., Kaelber, D. C., & Xu, R. (2025). Timing of neurorehabilitation and subsequent Alzheimer's disease risk in patients with moderate to severe traumatic brain injury: A nationwide retrospective cohort study in the United States. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877251385262
Vancouver
Kennemer AA, Gao Z, Davis PB, Kaelber DC, Xu R. Timing of neurorehabilitation and subsequent Alzheimer's disease risk in patients with moderate to severe traumatic brain injury: A nationwide retrospective cohort study in the United States. Journal of Alzheimer’s Disease. 2025. doi:10.1177/13872877251385262
BibTeX
@article{Kennemer2025,
author = {Kennemer, Austin A and Gao, Zhenxiang and Davis, Pamela B and Kaelber, David C and Xu, Rong},
title = {Timing of neurorehabilitation and subsequent Alzheimer's disease risk in patients with moderate to severe traumatic brain injury: A nationwide retrospective cohort study in the United States},
journal = {Journal of Alzheimer’s Disease},
year = {2025},
doi = {10.1177/13872877251385262}
}
EUVIMED